Molecular Mediators of Nerve Injury Signaling
September 19, 2011 updated by: Rambam Health Care Campus
Specific proteins and other signaling molecules are increased and decreased following nerve injury.
Some of these are important in producing pain or explaining why pain persists after traumatic nerve injuries or in disease states such as diabetes.
In this study, the investigators hypothesize that it is possible to detect changes in specific signaling molecules and that these will provide insights into novel treatment strategies.
The patients to be included are those who are undergoing the removal of tissue during surgery.
The tissues that would otherwise be discarded will be included in the study as appropriate.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Haifa, Israel, 31096
- Rambam Health Care Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing surgical procedures at Rambam Health Care Campus wherein the surgeon and PI determine appropriateness for study
Description
Inclusion Criteria:
- patients undergoing surgery where tissue removal is anticipated
Exclusion Criteria:
- age younger than 18
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Diabetes
|
|
Nerve injury
|
|
Other
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Anticipated)
September 1, 2016
Study Registration Dates
First Submitted
September 19, 2011
First Submitted That Met QC Criteria
September 19, 2011
First Posted (Estimate)
September 20, 2011
Study Record Updates
Last Update Posted (Estimate)
September 20, 2011
Last Update Submitted That Met QC Criteria
September 19, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0356-11-RMB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.